Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Merger or Acquisition (June 2025)
11 slides from Jb Chemicals & Pharmaceuticals's merger presentation, Jun 30, 2025
Slide 1: Exchange filing cover letter: Investor Presentation
June 30, 2025 National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G-Block, Bandra Kurla Complex, Bandra (E), Mumbai – 400051. Stock Symbol: JBCHEPHARM Dear Sir, Subject: Investor Presentation Enclosed please find the Investor Presentation by the Company. Kindly take the
Slide 2: Investor Presentation: Acquisition by Torrent Pharmaceuticals followed by merger
Investor Presentation Acquisition by Torrent Pharmaceuticals followed by merger
Slide 3: Overview
Overview ®
Slide 4: Overview & Strategic Rationale
Overview & Strategic Rationale o One of the fastest growing domestic pharma companies in India with a track record of building large brands and presence JB Pharma across 40+ countries Overview o India business contributes 58% of revenue with 6 brands in IPM Top 300 and 3 brands in Top 25 in the card
Slide 5: Transaction
Transaction o Acquisition of 46.39%1 stake in JB Pharma by Torrent for a cash consideration of INR 11,917 cr (INR 1,600 price per share) via execution of Share Purchase Agreement (“SPA”) Transaction o SPA transaction to trigger Mandatory Tender Offer for 26% stake at a price of INR 1,639.18 per shar
Slide 6: JB Pharma & Torrent Pharma at a glance
JB Pharma & Torrent Pharma at a glance
Slide 7: JB Pharma at a Glance
JB Pharma at a Glance Proven Market Outperformer with Scalable Platform Revenue Split by Business Verticals API, 2% 49 58% Top 5 1.8x 6 Chronic Years of Legacy India Revenue CDMO of Lozenges Outperformance Brands in IPM Top Globally International, to Market 300 29% India, 58% 3 17th 5,600+ 8 40+ Bra
Slide 8: Torrent Pharma at a Glance
Torrent Pharma at a Glance Specialty focused pharma powerhouse with a strong India and global presence Revenue Split by Business Verticals Others, 60+ 56% 7th ~76% 21 14% United States, Years of Legacy India Revenue Rank in IPM Chronic & sub- Brand in Top 500 10% chronic share (IPM) Brazil, 10% Indi
Slide 9: Combined Entity Ranking
Combined Entity Ranking
Slide 10: Combined Entity: Amongst the Top Players in IPM
Combined Entity: Amongst the Top 5 Players in IPM Ranking based on IQVIA Secondary Sales dataset as on MAT Mar’25 Ranking based on SMSRC Prescription dataset as on MAT Feb’25 Rank MAT (INR crs for Mar’25) % MS Absolute Prescriptions % MS Rank 1 Peer A 18,497 7.9% 1 Peer A 6,77,882 7.4% 2 Peer B 14,6
Slide 11: Thank you
GOOD PEOPLE E for GOOD HEALTH Thank you 000 www. jbpharma.com
J.B. Chemicals & Pharmaceuticals — Merger or Acquisition (June 2025) on 6ix